The $400 Oura Ring Is Going Public in a $2.2 Billion IPO, and Eli Lilly Wants In

Key Takeaways

• Oura, the smart-ring maker, has priced its IPO, setting a range of $40-44 per share to raise up to roughly $2.1-2.2 billion, at a fully diluted valuation of around $14-15 billion. It plans to list on the Nasdaq under the ticker OURA.
• Eli Lilly is a cornerstone investor: the pharma giant, alongside Dragoneer, has indicated interest in around $400 million of the deal (~19%), a notable vote of confidence from a major healthcare name.
• The business is growing fast: about 5 million paid members (up ~100% year-on-year), ~85% retention, and revenue of roughly $1.4 billion (up ~74%), but it is not yet profitable, posting a large net loss.
• A key catch: this is a "secondary-heavy" deal, roughly 73% of the shares on offer are being sold by existing investors cashing out, not raised by the company for growth. That's worth understanding.
• The takeaway: a buzzy, celebrity-backed IPO with real momentum, but IPOs are volatile, this one is loss-making and richly valued, and a famous product doesn't guarantee a good investment.
• Research it your way: you can invest in global stocks and ETFs from just $1 with zero commission on the Nemo.money app.

The smart ring is about to hit the stock market. Oura, the Finnish-American maker of the popular $400 health-tracking ring, has priced its initial public offering (IPO), setting the terms for one of the most closely watched consumer-tech listings of the year. It's raising up to around $2.1-2.2 billion at a valuation near $14-15 billion, it will trade on the Nasdaq under the ticker OURA, and, notably, pharma giant Eli Lilly is among its cornerstone backers.

For investors, a high-profile IPO like this is exciting, but exciting is exactly when a cool head matters most. This guide breaks down the terms, the business, what to watch as it lists, and the honest catches. It's educational, not investment advice, and OURA is an example to research, not a recommendation. If it prompts you to research the theme, you can explore global stocks and ETFs from just $1 with zero commission on the Nemo.money app.

Investors around the world are searching:

• "Oura IPO"
• "OURA stock"
• "Oura IPO price"
• "Oura ring stock"
• "should I buy Oura IPO"

The IPO Terms, in Plain English

Here's exactly what Oura has announced:

• 💵 Price and size. Oura is offering 50 million shares at a range of $40 to $44 each, aiming to raise up to roughly $2.1-2.2 billion. At the top of the range, that implies a fully diluted valuation of around $14-15 billion.
• 🏷️ The ticker. It plans to list on the Nasdaq under the symbol OURA.
• 📉 A lower valuation than first mooted. Earlier reports suggested Oura might target $16 billion or more. The priced range (~$14-15 billion) is a touch below that, a reminder that IPO valuations often get trimmed to meet real investor demand.
• 🏦 Big-name backing. Eli Lilly (the pharmaceutical giant behind blockbuster weight-loss drugs) and investment firm Dragoneer have indicated interest in around $400 million of the offering, roughly 19% of the deal. Cornerstone investors like these lend credibility to a listing.

The Catch Most People Miss: This Is a "Secondary-Heavy" IPO

This is the single most important nuance for investors, and it's easy to overlook.

• 🔍 Most of the shares are being sold by existing investors, not the company. Of the 50 million shares on offer, only about 13.5 million are new shares being sold by Oura itself (to raise money for the business). The other ~36.5 million, roughly 73%, are being sold by existing shareholders (early investors and insiders) cashing in some of their stake.
• ⚖️ Why that matters. In a "primary" share sale, the money raised goes into the company to fund growth. In a "secondary" sale, it goes to the sellers. A heavily secondary IPO isn't necessarily bad, early backers taking some money off the table is normal, but it does mean most of the proceeds aren't funding Oura's future growth, and it's worth knowing who's buying and who's selling.
• 💡 The lesson. Always look at how much of an IPO is new money for the company versus existing owners selling. It tells you a lot about what the listing is really for.

Meet the Business: What Oura Actually Is

Beyond the hype, Oura is a genuinely interesting company:

• 💍 A distinctive product. Oura makes a finger-worn smart ring (the latest is priced around $399-499) that tracks sleep, heart rate, temperature, stress, activity and women's health, paired with an app and a paid membership that turns the readings into personalised, AI-assisted health insights. Its screen-free design lasts about a week on a charge, a contrast to constantly-pinging smartwatches.
• 📈 Rapid growth. Oura had about 5 million paid members as of mid-2026, up roughly 100% year-on-year, with an impressive ~85% 12-month retention rate. Revenue reached roughly $1.4 billion over the past year, up about 74%.
• 🔁 A hardware-plus-subscription model. Around 80% of revenue comes from selling rings, and about 20% from recurring memberships (around $5.99 a month). That growing subscription base is a key part of the investment story, recurring revenue is valuable.
• 🌟 Celebrity cachet. Famous fans (reportedly including Jennifer Aniston, Prince Harry, Kim Kardashian and Tom Holland) have boosted its profile, helping it stand out in a crowded wearables market.

The Competition: A Crowded, Fierce Wearables Market

Oura leads the smart-ring niche, but it operates in one of the most competitive corners of consumer tech, and, importantly for investors, most of its rivals are either private or just one small part of a giant company. Here's the landscape (names are examples to research, not recommendations):

• ⌚ Apple (NASDAQ: AAPL), the Apple Watch. The dominant force in wearables overall. The Apple Watch tracks heart rate, activity, sleep and more, and Apple is reportedly deepening its health ambitions. The catch for investors: wearables are a tiny slice of Apple's trillion-dollar business, so the Watch barely moves Apple's stock, it's not a "pure" wearables play.
• 💪 Google / Alphabet (NASDAQ: GOOGL), Fitbit. Google owns Fitbit, one of the original fitness-tracker brands, and builds its own Pixel Watch. Again, though, Fitbit is a rounding error inside Alphabet's search-and-cloud empire, exposure to the wearables theme, but heavily diluted.
• 🧭 Garmin (NYSE: GRMN). A more focused play: Garmin makes premium sports watches and fitness devices with a loyal following among runners, cyclists and outdoor athletes, and it's consistently profitable. It's one of the more direct listed ways to research the fitness-wearables theme.
• 📱 Samsung (KRX: 005930), the Galaxy Ring and Watch. Samsung launched its own smart ring, putting it in direct competition with Oura in the ring niche, plus its Galaxy Watch line. As with Apple and Google, wearables are a small part of a vast electronics conglomerate (and Samsung is listed in South Korea, so access varies).
• 🏃 Whoop (private). A well-funded, screen-free fitness-tracking rival (reportedly valued around $10 billion) popular with athletes. Like Oura before this IPO, it's privately held, so there's no Whoop stock to buy, yet.

The key takeaway for investors: Oura's appeal is that it's a rare (soon-to-be) pure-play on health wearables, most listed alternatives are giants for whom wearables barely register, or private companies you can't buy. That focus is part of Oura's investment story, but it also means it faces competitors with far deeper pockets.

What to Watch as It Lists

If you're following the IPO, here's what actually matters:

• 🎢 First-day pop, and what follows. Buzzy IPOs often "pop" on day one, then can be volatile for weeks or months as the initial excitement settles and more shares become tradable. A big first-day jump is not the same as a good long-term investment. (We unpacked exactly how this works in our guide to what a hot IPO really means, and more broadly in our explainer on how IPOs really perform.)
• 🔒 Lock-up periods. Insiders and early investors are typically restricted from selling more shares for a set period (often 90-180 days) after listing. When that "lock-up" expires, a wave of shares can hit the market and pressure the price, a key date to be aware of.
• 💰 The path to profit. Oura is growing fast but is not yet profitable (it reported a large net loss). Watch whether it can turn its rapid growth and recurring memberships into sustainable profits.
• ⚔️ Competition. The wearables market is fierce: Samsung has its own ring, Whoop is a well-funded rival, and Apple Watch and Fitbit dominate the wrist. Oura leads the smart-ring niche, but rivals are circling.

The Honest Risks

• ⚠️ IPOs are volatile. New listings can swing sharply, and buying in the early days (often at peak hype) is risky. The price can fall well below the IPO price.
• ⚠️ Not yet profitable. Oura posted a large net loss over the past year. Fast growth is promising, but profits are what ultimately support a share price.
• ⚠️ A rich valuation. At ~$14-15 billion for a loss-making hardware-and-subscription company, a lot of future growth is already priced in.
• ⚠️ Secondary-heavy deal. Most of the shares on offer are insiders selling, not new money for growth, understand what you're buying into.
• ⚠️ A legal cloud. Oura has faced a proposed class-action lawsuit alleging its rings overstate how accurately they measure sleep stages (Oura has pushed back). Legal and accuracy questions are worth monitoring.
• ⚠️ Competition and hardware cyclicality. Gadget demand can be cyclical and fashion-driven, and bigger rivals have deep pockets.

The takeaway: Oura's IPO is a genuinely exciting moment for a fast-growing, distinctive company with serious backers, including Eli Lilly. But a buzzy listing, a loss-making business, a rich valuation and a secondary-heavy structure all mean the excitement and the investment case need to be judged separately. Research it, understand what you'd actually be buying, and never let IPO hype do your thinking.

How to Research IPOs and Wearables Stocks with Nemo.money

Whether you're following Oura, the wider wearables and health-tech theme, or how to approach IPOs, the Nemo.money app is built to help you research before you decide:

• Invest from Just $1: Fractional shares let you start small with stocks and ETFs.
• Zero-Commission Trading: Buy and sell US-market stocks and ETFs without commission fees.
• AI-Powered Insights & Nemes: Explore data, sentiment and curated themed collections (Nemes), including technology, health and wearables themes, as a research starting point (for research, not recommendations).
• Earn 6% AER on Idle Cash: Uninvested cash in your wallet earns 6% AER, paid daily in USD, while you research and decide.

Frequently Asked Questions (FAQs)

What is Oura's IPO price and valuation?

Oura has priced its IPO at a range of $40 to $44 per share, offering 50 million shares to raise up to roughly $2.1-2.2 billion. At the top of the range, that implies a fully diluted valuation of around $14-15 billion. Oura plans to list on the Nasdaq under the ticker OURA. This is slightly below the $16 billion-plus valuation earlier reports had suggested.

Why is Eli Lilly investing in Oura?

Eli Lilly, the pharmaceutical giant known for its blockbuster diabetes and weight-loss drugs, is a cornerstone investor in Oura's IPO, indicating interest (with investment firm Dragoneer) in around $400 million of the deal, roughly 19%. Big, credible cornerstone investors lend confidence to a listing, and Lilly's interest reflects the growing overlap between healthcare, pharma and consumer health-tracking wearables. It's a notable validation, though it doesn't guarantee the stock will perform well.

What does "secondary-heavy IPO" mean, and why does it matter for Oura?

In Oura's IPO, of the 50 million shares offered, only about 13.5 million are new shares sold by the company (raising money for its growth). The other ~36.5 million (roughly 73%) are being sold by existing investors and insiders cashing in part of their stake, this is the "secondary" portion. It matters because most of the money raised goes to those sellers, not into the business. A secondary-heavy deal isn't necessarily bad (early backers often take some money off the table), but investors should understand that the listing is largely about existing owners selling, not funding new growth.

Is the Oura IPO a good investment?

That depends entirely on your own research, goals and risk tolerance, and this isn't advice. Oura is a fast-growing, distinctive company (5 million paid members, ~74% revenue growth, strong retention, big-name backers), but it's not yet profitable, carries a rich ~$14-15 billion valuation, is a secondary-heavy listing, faces fierce competition and a legal challenge, and, like all IPOs, could be very volatile. A famous product and a buzzy listing don't guarantee a good investment. Research it carefully and treat it as an example to research, not a recommendation.

When can I buy Oura shares?

Once Oura completes its IPO and its shares begin trading on the Nasdaq under the ticker OURA, investors will typically be able to buy them through a brokerage or investing app. Note that ordinary investors usually buy after trading begins (at the market price, which can differ from the IPO price), rather than at the IPO price itself, which mainly goes to institutional and cornerstone investors. IPO shares can be volatile in early trading. Check the latest listing details, and remember your capital is at risk.

Final Thoughts: A Buzzy Listing, but Read the Fine Print

Oura going public is a landmark moment for the smart-ring category and a fascinating consumer-tech IPO, a genuinely distinctive product, rapid growth, loyal members, celebrity fans, and the backing of a pharma heavyweight in Eli Lilly. There's real substance behind the buzz.

But a great product and a great investment are different questions, and IPOs are where that gap most often catches people out. Oura is arriving loss-making, richly valued, with most of the shares on offer being sold by insiders rather than raised for growth, and against fierce, deep-pocketed competition. None of that makes it a bad investment or a good one; it makes it one that demands genuine research rather than hype-driven enthusiasm. If you're tempted, understand the terms, watch the lock-ups and the path to profit, weigh the valuation, and decide with your head, not the headlines. In IPOs above all, patience and homework tend to beat excitement.

Explore global stocks and ETFs from $1 with zero commission on the Nemo.money app.

Nemo = Never Miss Out.

Stay informed. Stay ahead.

#Oura #IPO #Investing #Wearables #NemoMoney

Terms and conditions apply. This is not investment advice. Past performance is not indicative of future results. Your capital is at risk. See website for Risk Disclosure. Exinity ME Ltd (https://nemo.money) is regulated by ADGM's Financial Services Regulatory Authority.

‍